Duloxetine Capsule, Delayed Release
Product Images NDC 71335-2624

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71335-2624). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 01)

Chemical structure diagram depicting duloxetine hydrochloride, showing its molecular framework including a naphthalene group, a thiophene ring, and the amine hydrochloride moiety.*

FDA Label Image

Figure 1 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 02)

A Kaplan-Meier survival curve chart comparing the proportion of patients with relapse over time (days) between Duloxetine and placebo treatments. The graph shows relapse proportion on the vertical axis and time from randomization to relapse on the horizontal axis, with Duloxetine and placebo represented by separate lines according to the Kaplan-Meier estimator method.*

FDA Label Image

Figure 2 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 03)

A Kaplan-Meier estimator graph comparing the proportion of patients with relapse over time in days from randomization between two treatments: placebo (dashed line) and duloxetine (solid line). The graph shows a lower relapse proportion for duloxetine compared to placebo throughout the study period.*

FDA Label Image

Figure 1 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 04)

A line graph depicting the percentage of patients improved versus the percent improvement in pain from baseline. The graph compares four groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo, showing patient response across increasing pain improvement thresholds.*

FDA Label Image

Figure 2 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 05)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg administered twice daily (BID), Duloxetine 60 mg once daily (QD), and placebo, showing higher patient improvement percentages for Duloxetine groups compared to placebo at various pain improvement levels.*

FDA Label Image

Fig 5 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 06)

A line graph depicting the percentage of patients improved plotted against the percent improvement in pain from baseline. The graph compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, showing patient improvement trends across various pain improvement percentages.*

FDA Label Image

Fig 6 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 07)

A line graph illustrating the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at different dosages (120 mg twice daily, 60 mg once daily, 60 mg once daily in a different dataset) and placebo. The x-axis shows percent improvement from >0 to 100, and the y-axis shows percentage of patients improved from 0 to 100%. Four lines represent each treatment group.*

FDA Label Image

Fig 7 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 08)

A line graph showing the percentage of pediatric patients aged 13 to 17 years with juvenile fibromyalgia syndrome achieving various levels of pain relief at week 12. The x-axis represents percent improvement in pain from baseline, while the y-axis shows the percentage of patients improved. Two lines compare Duloxetine 60 mg once daily and placebo groups.*

FDA Label Image

Figure 8 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 09)

A line graph depicting the percentage of patients improved relative to percent improvement in pain from baseline (BOCF). Two lines compare placebo and Duloxetine 60/120 mg once daily, showing patient improvement rates across various pain improvement percentages.*

FDA Label Image

Figure 9 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 10)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). Two lines compare Placebo and Duloxetine 60 mg once daily, with Duloxetine showing a higher percentage of patients improved at various pain improvement levels.*

FDA Label Image

Figure 10 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 11)

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline (BOCF) for placebo and Duloxetine 60/120 mg once daily. The x-axis represents percent improvement in pain, while the y-axis shows the percentage of patients improved. Two curves show a higher percentage of improvement over placebo for Duloxetine.*

FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 935 1)

Packaged bottle of Duloxetine 20 mg delayed-release capsules. The label displays the brand and generic name prominently, specifying the oral route and human prescription use. The pack is manufactured by Bryant Ranch Prepack, with an NDC of 71335-2624. The bottle appears white with a child-resistant cap.*

FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 942 1)

The image shows a carton of Duloxetine 20 mg delayed-release oral capsules by Bryant Ranch Prepack. The front panel displays the product name, strength, dosage form, and labeler information. The packaging features a stylized black and gray floral pattern against a white background with red accent lines.*

FDA Label Image

Label (Lbl713352624)

Duloxetine Delayed-Release Capsules, USP 20 mg, shown on a rectangular label. The label indicates packaging of 30 capsules and includes the NDC 71335-2624-1. It is repackaged by Bryant Ranch Prepack and manufactured by Lupin Limited. The label contains storage instructions, dosage content information, and a QR code linking to the package insert.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.